<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 12">
<meta name=Originator content="Microsoft Word 12">
<link rel=File-List href="ADME_tox_files/filelist.xml">
<link rel=Edit-Time-Data href="ADME_tox_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><o:SmartTagType
 namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="City"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>every1</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Dan Fara</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1231</o:TotalTime>
  <o:Created>2008-01-07T11:54:00Z</o:Created>
  <o:LastSaved>2008-01-07T11:54:00Z</o:LastSaved>
  <o:Pages>4</o:Pages>
  <o:Words>1160</o:Words>
  <o:Characters>6612</o:Characters>
  <o:Lines>55</o:Lines>
  <o:Paragraphs>15</o:Paragraphs>
  <o:CharactersWithSpaces>7757</o:CharactersWithSpaces>
  <o:Version>12.00</o:Version>
 </o:DocumentProperties>
</xml><![endif]-->
<link rel=dataStoreItem href="ADME_tox_files/item0001.xml"
target="ADME_tox_files/props0002.xml">
<link rel=themeData href="ADME_tox_files/themedata.thmx">
<link rel=colorSchemeMapping href="ADME_tox_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>5.5 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="--"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="267">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="59" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1107304683 0 0 159 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750139 0 0 159 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Footnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";}
span.MsoFootnoteReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	vertical-align:super;}
span.MsoEndnoteReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Endnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Endnote Text";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Footnote Text";}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("ADME_tox_files/header.htm") fs;
	mso-footnote-continuation-separator:url("ADME_tox_files/header.htm") fcs;
	mso-endnote-separator:url("ADME_tox_files/header.htm") es;
	mso-endnote-continuation-separator:url("ADME_tox_files/header.htm") ecs;
	mso-endnote-numbering-style:arabic;}
@page Section1
	{size:8.5in 11.0in;
	margin:.5in .5in .5in .5in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;
	mso-endnote-numbering-style:arabic;}
 /* List Definitions */
 @list l0
	{mso-list-id:1607881650;
	mso-list-template-ids:-2014121618;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l1
	{mso-list-id:1710178801;
	mso-list-type:hybrid;
	mso-list-template-ids:1679559714 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l1:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2
	{mso-list-id:2004970411;
	mso-list-type:hybrid;
	mso-list-template-ids:-941201304 -1155752650 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";}
table.MsoTableGrid
	{mso-style-name:"Table Grid";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-priority:59;
	mso-style-unhide:no;
	border:solid black 1.0pt;
	mso-border-alt:solid black .5pt;
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-border-insideh:.5pt solid black;
	mso-border-insidev:.5pt solid black;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><i style='mso-bidi-font-style:normal'><span style='font-size:16.0pt;
line-height:115%;font-family:"Times New Roman","serif"'>Section III</span></i></b><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;line-height:
115%;font-family:"Times New Roman","serif"'><span style='mso-tab-count:1'> </span><o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;
line-height:115%;font-family:"Times New Roman","serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;
line-height:115%;font-family:"Times New Roman","serif"'>Cheminformatics - Advanced:
</span></b><i><span style='font-size:14.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>The role of pharmacokinetics/toxicity
and the concept of drug-likeness</span></i><b style='mso-bidi-font-weight:normal'><span
style='font-size:14.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"'>Andrei
Leitão, Dan C. Fara <span style='mso-spacerun:yes'> </span>and Tudor I. Oprea<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Up to now
many pharmacodynamic properties were taken into account, basically considering
the ligand-target interactions. Nonetheless, a good drug candidate does not
rely only on a good fit and the best match of hydrophobic and lipophilic
interactions with the target macromolecule. In fact, there must be a compromise
with many different properties that compose the pharmacokinetic profile of a
compound. While pharmacodynamics deals with the compound-target interaction,
the pharmacokinetics takes into consideration all the steps that the compound
should go to reach the site of interaction – see Figure 1<a style='mso-endnote-id:
edn1' href="#_edn1" name="_ednref1" title=""><span class=MsoEndnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[1]</span></span><![endif]></span></span></a>. A
compound must be bioavailable in a good extend in order to reach the site of
action. For oral drugs, it means that it should be soluble and permeate through
the enterocyte, being metabolized into the liver and distributed into the
bloodstream.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:315.75pt;
 height:222.75pt'>
 <v:imagedata src="ADME_tox_files/image001.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=421 height=297
src="ADME_tox_files/image002.gif" v:shapes="_x0000_i1025"><![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
line-height:115%;font-family:"Times New Roman","serif";mso-fareast-font-family:
"Times New Roman";mso-bidi-font-style:italic'>Figure 1</span></b><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>.
Representation of the pharmacokinetics process and different models in use to
study the pharmaceutical profile (taken from reference 1).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Basically,
the pharmacokinetics is composed by the absorption, distribution, metabolism
and excretion. Together with the toxicity studies, they are the so called
ADME-Tox (also found as ADMET). This plethora of events that takes place before
the pharmacodynamics represents nowadays the main drawback in the drug
development phase, increasing the attrition rate to the process (i.e. rate of
failure to develop a new compound).<a style='mso-endnote-id:edn2' href="#_edn2"
name="_ednref2" title=""><span class=MsoEndnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[2]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>The high
rate of failure impairs the development of many new compounds that are not
considered to be attractive drug candidates after the pharmaceutical companies
have spent years of work and millions of dollars. Therefore, it is expected
that the integration of the ADME-Tox knowledge and other global properties
(drug-likeness, among others) can streamline the drug discovery &amp;
development pipeline.<a style='mso-endnote-id:edn3' href="#_edn3"
name="_ednref3" title=""><span class=MsoEndnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[3]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Early
ADME studies in the end of the nineteen century showed that there was a
correlation between the narcotic property of some compounds and the solubility
in oil, but the first quantitative evidence came with the Hansch studies in the
60’s, which showed the correlation between the logarithmic of the octanol/water
partition coefficient (log P or log P<sub>o/w</sub>) and the biological
activity. The octanol-water system is considered the first useful model to the
partition in the membrane of a cell. The method is straightforward, where a
compound is added to a separation funnel with two liquids (water and octanol)
and, after shacking it, the concentration of the molecule in each liquid is
measured. Hydrophilic compounds tend to stay in the aqueous solution, while
more hydrophobic ones are buried in the octanol moiety. The result of this
balance is described by <i>P</i> (the partition parameter) meaning that the lower
it goes, the more compound accumulates into the hydrophilic part (consequently
it can be considered as a hydrophilic molecule).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Many
studies throughout the last and this century reinforce the importance of taking
into account the log P of a compound as a good metric of the compound permeability
profile. Too hydrophilic compounds should not be considered good drug
candidates because they are not able to cross the membrane using the passive
diffusion. On the other hand, too hydrophobic compounds tend to be insoluble,
forming aggregates, which are font of the many false-positive results got in
the high-throughput screening (HTS). Studies with different classes of
compounds showed that CNS drugs (i.e. molecules that act at the Central Nervous
System) use to have higher log P value than other classes of drugs, once they
should cross the Blood-Brain Barrier (BBB).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Methods
for calculating the log P are now available, based on different sets of rules
and concepts. The most popular one is known as Clog P, which is based on the
Hansch and Leo studies on thousands of molecules and comprise the biggest
measured log P dataset available so far – see Figure 2.<o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-yfti-tbllook:1184;mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
  <td width=101 style='width:75.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:51.75pt;height:57.75pt'>
   <v:imagedata src="ADME_tox_files/image003.png" o:title="Desipramine"/>
  </v:shape><![endif]--><![if !vml]><img width=69 height=77
  src="ADME_tox_files/image004.gif" v:shapes="_x0000_i1026"><![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Desipramine<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>4.5<o:p></o:p></span></p>
  </td>
  <td width=122 style='width:91.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:80.25pt;height:54.75pt'>
   <v:imagedata src="ADME_tox_files/image005.png" o:title=""/>
  </v:shape><![endif]--><![if !vml]><img width=107 height=73
  src="ADME_tox_files/image006.jpg" v:shapes="_x0000_i1027"><![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Chlorpromazine<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>5.3<o:p></o:p></span></p>
  </td>
  <td width=120 style='width:90.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
   id="_x0000_i1028" type="#_x0000_t75" style='width:74.25pt;height:59.25pt'>
   <v:imagedata src="ADME_tox_files/image007.png" o:title="Diclofenac"/>
  </v:shape><![endif]--><![if !vml]><img width=99 height=79
  src="ADME_tox_files/image008.gif" v:shapes="_x0000_i1028"><![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Acetaminofen<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>4.7<o:p></o:p></span></p>
  </td>
  <td width=179 style='width:134.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
   id="_x0000_i1029" type="#_x0000_t75" style='width:122.25pt;height:42.75pt'>
   <v:imagedata src="ADME_tox_files/image009.png" o:title="Haloperidol"/>
  </v:shape><![endif]--><![if !vml]><img width=163 height=57
  src="ADME_tox_files/image010.gif" v:shapes="_x0000_i1029"><![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Haloperidol<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>3.8<o:p></o:p></span></p>
  </td>
  <td width=211 style='width:157.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
   id="_x0000_i1030" type="#_x0000_t75" style='width:44.25pt;height:36.75pt'>
   <v:imagedata src="ADME_tox_files/image011.png" o:title="Aspirin"/>
  </v:shape><![endif]--><![if !vml]><img width=59 height=49
  src="ADME_tox_files/image012.gif" v:shapes="_x0000_i1030"><![endif]><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Aspirin
  </span><span style='font-size:10.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>(</span><span
  style='font-size:10.0pt;line-height:115%;font-family:"Times New Roman","serif"'>acetylsalicylic
  acid)</span><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
  justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>1.2<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
line-height:115%;font-family:"Times New Roman","serif";mso-fareast-font-family:
"Times New Roman";mso-bidi-font-style:italic'>Figure 2</span></b><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>. Clog P
values of some drugs<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>But, is
there an optimal range for log P? This question arose as expected in the
scientific community and, together with many others, led to the research on
this still very young field. Studies have been evolving from the description of
these phenomena to the collection of data and standardization of methods in
order to select and, if possible, predict better molecules based on
computational models. The seminal work of Lipinski published in 1997 shed light
to this complex problem by means of a truly easy way.<a style='mso-endnote-id:
edn4' href="#_edn4" name="_ednref4" title=""><span class=MsoEndnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[4]</span></span><![endif]></span></span></a>
Analyzing the set of oral drugs in the market at that time using the following
calculated parameters (log P, molecular weight = MW, number of hydrogen bond
donors = HBD, and hydrogen bond acceptors = HBA) it came to the conclusion
that:<o:p></o:p></span></p>

<ol style='margin-top:0in' start=1 type=1>
 <li class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo3'><span style='font-size:12.0pt;line-height:
     115%;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-bidi-font-style:italic'>there are some optimal ranges for oral drugs:
     MW &#8804; 500, HBA &#8804; 10, HBD &#8804; 5, ClogP &#8804; 5;<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo3'><span style='font-size:12.0pt;line-height:
     115%;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-bidi-font-style:italic'>oral drugs usually do not violate more than
     one these ranges.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>This
simple set of descriptors could define the profile of oral drugs and, because
of its multiplicity of five, it was so called ‘rule of five’ (and sometimes
Lipinski’s rule). The main objective of this work was to advise the scientific
community about the usefulness of such a set of descriptors as a guide to the
drug discovery of new molecules, avoiding structures with are far outside these
limits, because the higher probability of the attrition rate in the further
steps of the process. By doing that, the new concept of drug-likeness (i.e.
compounds that have properties similar to drugs) was born. Further studies in
this area not only expanded the rule of five and better defined the drug-like
term, but also provided similar concepts for leads<a style='mso-endnote-id:
edn5' href="#_edn5" name="_ednref5" title=""><span class=MsoEndnoteReference><span
style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[5]</span></span><![endif]></span></span></a> and
chemical fragments.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Many
other models are available to describe the permeability of a drug. For example,
Caco-2 and MDCK cell lines and PAMPA (Parallel Artificial Membrane Permeation
Assay) are used to check if a compound can permeate the membrane and also the
mechanism. Nowadays, these cellular assays can be done under a HTS platform,
where compound libraries are tested. The main drawback of these cellular
systems is the time to grow the cell monolayer, once that the assay times are
short.<a style='mso-endnote-id:edn6' href="#_edn6" name="_ednref6" title=""><span
class=MsoEndnoteReference><span style='mso-special-character:footnote'><![if !supportFootnotes]><span
class=MsoEndnoteReference><span style='font-size:12.0pt;line-height:115%;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
mso-bidi-font-style:italic'>[6]</span></span><![endif]></span></span></a><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>The
compound metabolism can be studied using microsomes (cellular assay) and/or
CYP450 (Cytocrome P450) enzymes in enzymatic assays. Nowadays, molecular
modeling is also another tool used to understand the mechanism of catalysis
provided by these enzymes, considering also the wide range of scaffolds that
are substrates of those enzymes. Of particular concern today are the enzymes
CYP405 2D6 and 3A4, which are responsible for the metabolism of many drug
classes. Some models were also developed based on the current knowledge in the
field in order to predict drug metabolism, but are still limited to some
classes and enzymes, due to the limitation of the databases. This is the case
of MetaSite, new software that was built based on the CYP2D6 and CYP3A4
three-dimensional structures together with the metabolic profile of some
compound classes.<a style='mso-endnote-id:edn7' href="#_edn7" name="_ednref7"
title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA;mso-bidi-font-style:italic'>[7]</span></span><![endif]></span></span></a>
Certainly, these models still deserve improvement, but they are providing to be
useful in a near future – see Figure 3.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>Some
models for distribution and toxicity are still in the beginning. It is
especially hard to figure out the toxic profile of a compound. The excretion of
compounds usually depends on the metabolism and there are no good models that
can be used in a HTS assay.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'><!--[if gte vml 1]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:278.25pt;height:224.25pt'>
 <v:imagedata src="ADME_tox_files/image013.emz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=371 height=299
src="ADME_tox_files/image014.gif" v:shapes="_x0000_i1031"><![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
line-height:115%;font-family:"Times New Roman","serif";mso-fareast-font-family:
"Times New Roman";mso-bidi-font-style:italic'>Figure 3</span></b><span
style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-style:italic'>. Prediction
of metabolic sites for some compounds based on homology model and the
three-dimensional structure of the CYP450 2D6<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify'><span style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>

</div>

<div style='mso-element:endnote-list'><![if !supportEndnotes]><br clear=all>

<hr align=left size=1 width="33%">

<![endif]>

<div style='mso-element:endnote' id=edn1>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn1' href="#_ednref1"
name="_edn1" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[1]</span></span><![endif]></span></span></a>
Kerns, E. H.; Di. L.; Pharmaceutical Profiling in Drug discovery, <i
style='mso-bidi-font-style:normal'>Drug Discovery Today </i><b
style='mso-bidi-font-weight:normal'>2003</b>, <i style='mso-bidi-font-style:
normal'>8</i>, 316-323</p>

</div>

<div style='mso-element:endnote' id=edn2>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn2' href="#_ednref2"
name="_edn2" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[2]</span></span><![endif]></span></span></a>
Kubinyi, H.; Drug Research: Myths, Hype and Reality, <i style='mso-bidi-font-style:
normal'>Nature Reviews Drug Discovery </i><b style='mso-bidi-font-weight:normal'>2003</b>,
<i style='mso-bidi-font-style:normal'>2</i>, 665-668</p>

</div>

<div style='mso-element:endnote' id=edn3>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn3' href="#_ednref3"
name="_edn3" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[3]</span></span><![endif]></span></span></a>
Oprea, T. I.; Virtual Screening in Lead Discovery: A Viewpoint, <i
style='mso-bidi-font-style:normal'>Molecules </i><b style='mso-bidi-font-weight:
normal'>2002</b>, <i style='mso-bidi-font-style:normal'>7</i>, 51-62</p>

</div>

<div style='mso-element:endnote' id=edn4>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn4' href="#_ednref4"
name="_edn4" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[4]</span></span><![endif]></span></span></a>
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.; Experimental and
Computational Approaches to Estimate Solubility and Permeability in Drug
Discovery and Development Settings, <i style='mso-bidi-font-style:normal'>Advanced
Drug Delivery Reviews</i><b style='mso-bidi-font-weight:normal'> 1997</b>,<i
style='mso-bidi-font-style:normal'> 23</i>, 3-25</p>

</div>

<div style='mso-element:endnote' id=edn5>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn5' href="#_ednref5"
name="_edn5" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[5]</span></span><![endif]></span></span></a>
Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D.; Is There a Difference
between Leads and Drugs? A Historical Perspective,<i style='mso-bidi-font-style:
normal'> Journal of Chemical Information and Computer Sciences </i><b
style='mso-bidi-font-weight:normal'>2001</b>, <i style='mso-bidi-font-style:
normal'>41</i>, 1308-1315</p>

</div>

<div style='mso-element:endnote' id=edn6>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn6' href="#_ednref6"
name="_edn6" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[6]</span></span><![endif]></span></span></a>
Balimane, P. V.; Chong, S.; Cell Culture-Based Models for Intestinal
Permeability: A Critique, <i style='mso-bidi-font-style:normal'>Drug Discovery
Today </i><b style='mso-bidi-font-weight:normal'>2005</b>, <i style='mso-bidi-font-style:
normal'>10</i>, 335-343</p>

</div>

<div style='mso-element:endnote' id=edn7>

<p class=MsoEndnoteText><a style='mso-endnote-id:edn7' href="#_ednref7"
name="_edn7" title=""><span class=MsoEndnoteReference><span style='mso-special-character:
footnote'><![if !supportFootnotes]><span class=MsoEndnoteReference><span
style='font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif";
mso-fareast-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>[7]</span></span><![endif]></span></span></a>
Kjellander, B.; Masimirembwa, C. M.; <st1:City w:st="on">Zamora</st1:City>, I.;
Exploration of Enzyme-Ligand Interactions in CYP2D6 &amp; 3A4 Homology Models
and Crystal Structures Using a Novel Computational Approach, <i
style='mso-bidi-font-style:normal'>Journal of Chemical Information and Modeling</i>
<b style='mso-bidi-font-weight:normal'>2007</b>, <i style='mso-bidi-font-style:
normal'>47</i>, 1234-1247</p>

</div>

</div>

</body>

</html>
